Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2021 Publisher: GlaxoSmithKline NZ Limited, Private Bag 106600, Downtown, Auckland, New Zealand
SERETIDE Inhaler (with counter), 25 mcg/50 mcg, aerosol inhaler, metered dose.
SERETIDE Inhaler (with counter), 25 mcg/125 mcg, aerosol inhaler, metered dose.
SERETIDE Inhaler (with counter), 25 mcg/250 mcg, aerosol inhaler, metered dose.
| Pharmaceutical Form |
|---|
|
Aerosol inhaler, metered dose. The canisters are fitted into plastic actuators incorporating an atomising orifice and fitted with dustcaps. |
SERETIDE Inhaler 25 mcg/50 mcg: Each single actuation provides salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 50 micrograms of fluticasone propionate.
SERETIDE Inhaler 25 mcg/125 mcg: Each single actuation provides salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 125 micrograms of fluticasone propionate.
SERETIDE Inhaler 25 mcg/250 mcg: Each single actuation provides salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 250 micrograms of fluticasone propionate.
For the full list of excipients, see Section 6.1 List of excipients.
| Active Ingredient | Description | |
|---|---|---|
| Fluticasone |
Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. |
|
| Salmeterol |
Salmeterol is a selective long-acting (12 hour) β2 adrenoceptor agonist. These pharmacological properties of salmeterol offer more effective protection against histamine-induced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting β2 agonists. |
| List of Excipients |
|---|
|
Norflurane HFA 134a (a CFC-Free propellant) |
SERETIDE Inhaler comprises a suspension of salmeterol xinafoate and fluticasone propionate in the non-CFC propellant HFA 134a. The suspension is contained in an aluminium alloy can sealed with a metering valve. The canisters are fitted into plastic actuators incorporating an atomising orifice and fitted with dustcaps. The canister has a counter attached to it, which shows how many actuations of medicine are left. The number of actuations left will show through a window in the back of the plastic actuator. SERETIDE Inhaler has been formulated in three strengths and one pack size, delivering 120 actuations per inhaler.
GlaxoSmithKline NZ Limited, Private Bag 106600, Downtown, Auckland, New Zealand
25 January 2001
| Drug | Countries | |
|---|---|---|
| SERETIDE | Austria, Australia, Brazil, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
